Bendamustine Hydrochloride

NEW ORLEANS — Bendamustine lymphodepletion resulted in significant CAR T-cell expansion among patients with relapsed or refractory non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

Polatuzumab combined with bendamustine and rituximab demonstrated encouraging rates of complete response among patients with transplantation-ineligible, relapsed/refractory diffuse large B-cell lymphoma, according to results of a phase 1b/phase 2 trial published in Journal of Clinical Oncology.

In this video, Joshua Brody, MD, director of the lymphoma immunotherapy program at Tisch Cancer Institute at Mount Sinai, discusses major unmet needs in the treatment of follicular lymphoma, including challenges treating early relapsing patients.

In this video, Noah Merin, MD, PhD, from the Blood and Marrow Transplantation Program and assistant professor of medicine at Cedars-Sinai Medical Center, discussed first-line treatments and options for relapsed or refractory follicular lymphoma.

In this video, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program and Staff Physician at the Cleveland Clinic Taussig Cancer Institute, discussed how he approaches putting together a treatment plan for an MCL patient.

In this video, Bijal Shah, MD, MS, an associate professor in the malignant hematology department at Moffitt Cancer Center, discussed updates to the SHINE trial, and its role in the treatment of mantle cell lymphoma, as well as findings of ZUMA-2 and how it impacts clinical practice.